SPRY vs. MRUS, RARE, ARWR, PBH, HCM, CORT, FOLD, BHVN, DYN, and GERN
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Merus (MRUS), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Prestige Consumer Healthcare (PBH), HUTCHMED (HCM), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), Biohaven (BHVN), Dyne Therapeutics (DYN), and Geron (GERN). These companies are all part of the "pharmaceutical preparations" industry.
ARS Pharmaceuticals (NASDAQ:SPRY) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
ARS Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
In the previous week, Merus had 9 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 16 mentions for Merus and 7 mentions for ARS Pharmaceuticals. Merus' average media sentiment score of 0.70 beat ARS Pharmaceuticals' score of 0.50 indicating that Merus is being referred to more favorably in the news media.
Merus received 325 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave ARS Pharmaceuticals an outperform vote while only 65.94% of users gave Merus an outperform vote.
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
ARS Pharmaceuticals currently has a consensus target price of $18.50, suggesting a potential upside of 119.98%. Merus has a consensus target price of $73.60, suggesting a potential upside of 31.97%. Given ARS Pharmaceuticals' higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Merus.
ARS Pharmaceuticals has a net margin of 0.00% compared to Merus' net margin of -390.36%. ARS Pharmaceuticals' return on equity of -21.14% beat Merus' return on equity.
ARS Pharmaceuticals has higher earnings, but lower revenue than Merus. Merus is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ARS Pharmaceuticals beats Merus on 10 of the 17 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
